Tenofovir Disoproxil Fumarate
Hepatitis B Virus Infection
Explore 22 assets in Hepatitis B Virus Infection →Floatz Rating
B56/100
Confidence
Indicative
Sponsor
Oslo University Hospital
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03887702CT.gov Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors | — | Terminated | — | — | — |
NCT03957629CT.gov Optimized Treatment of Peginterferon Alfa 2a in Treatment Experienced Patients With HBV Related Liver Fibrosis | — | Unknown | — | — | — |
NCT03919565CT.gov Optimized Treatment of Peginterferon Alfa 2a/2b in Anti-virus Treatment Naive Patients With HBV Related Liver Fibrosis | — | Unknown | — | — | — |
NCT03920605CT.gov Optimized Treatment of Peginterferon Alfa 2a/2b in Treatment Experienced Patients With HBV Related Liver Fibrosis | — | Unknown | — | — | — |
NCT04196998CT.gov Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Hepatitis b Virus Related Compensated Cirrhosis | — | Unknown | — | — | — |
NCT05683548CT.gov Replicor Compassionate Access Program | — | No Longer Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatitis B Virus Infection
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tenofovir Disoproxil Fumarate (this asset) | Oslo University Hospital | P3 | B · 56 |
| Entecavir | Sun Yat-sen University | P4 | BBB |
| Lamivudine | Fudan University | P4 | BBB |
| Tenofovir | Ruijin Hospital | P4 | BB |
| Hepatitis B Virus Vaccine | Eunice Dube | P4 | BB |
| Tenofovir Bis(Isopropyloxycarbonyloxymethyl) Ester | West China Hospital | P4 | BB |
| Hep-V Vax | University of Oxford | P4 | BB |
| Tenofovir Alafenamide | Sun Yat-sen University | P4 | BB |
| Besifovir Dipivoxil | IlDong Pharmaceutical Co Ltd | P4 | BB |
+34 more in the Hepatitis B Virus Infection cohort
Other indications for Tenofovir Disoproxil Fumarate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| HIV Infectious Disease | — | P4 | BB · 70 |
| Chronic Hepatitis B Virus Infection | — | P4 | BB · 67 |
| Lipodystrophy | — | P4 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tenofovir Disoproxil Fumarate in Hepatitis B Virus Infection. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tenofovir-disoproxil-fumarate-hepatitis-b-virus-infection
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →